tailor the compounds for high affinity, selectivity, safety, and efficacy,
identify new modes of action for drug candidates,
enter design paths of allosteric modulators,
tap into unexplored IP and chemical spaces,
and increase efficiency of the drug pipeline.
- hit identification and optimization in challenging projects,
- faster cycle times from ligand to 3D structure,
- higher throughput of 3D-models for structural insight,
- flexible application of compound libraries in crystallographic screening.
OUR SCIENTIFIC APPROACH AND STRATEGIC VISION
CrystalsFirst is committed to the constant improvement and expansion of its technology platform to better unlock the strategic advantages of structure- and fragment-based drug discovery.
Our technology renders complex trial & error approaches obsolete, ascertains the druggability of a given target, and ensures early and unambiguous identification of binders by crystallographic analysis.
Dr. Serghei Glinca, MBA
Chief Executive Officer
Dr. Stefan Merkl
Chief Scientific Officer
Chief Financial Officer
Chief Operations Officer
Dr. Janis Müller
Scientific Advisory Board
Prof. Dr. Gerhard Klebe
Philipps University Marburg
Dr. Gerhard Müller
Gotham Therapeutics New York
Dr. Manfred S. Weiss
Helmholtz Zentrum Berlin
Marbacher Weg 6 | 35037 Marburg